Larimar Therapeutics (LRMR) Stock: Buy, Sell, or Hold?
LRMR - Larimar Therapeutics, Inc. Common Stock
$2.96
-0.10 (-3.27%)
▼
5d:
-3.74%
30d:
-23.51%
90d:
-10.03%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When LRMR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LRMR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: LRMR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: LRMR is currently trading at $2.96, which is considered oversold relative to its 30-day fair value range of $3.47 to $4.09.
Technical Outlook: Technically, LRMR is in a strong uptrend. The price is currently testing key support at $2.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $14.40 (+386.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LRMR is in a strong uptrend. The price is currently testing key support at $2.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $14.40 (+386.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.47 -
$4.09
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 386.5% below Wall St target ($14.40)
- NEUTRAL: Bottoming setup forming (45/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$3.47 -
$4.09
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.92
Resistance Level
$3.97
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.79
Wall Street Target
$14.40
(+386.5%)
Share & Embed Analysis
Last updated: October 03, 2026 4:36 AM ET
Data refreshes hourly during market hours. Next update: 5:36 AM
Data refreshes hourly during market hours. Next update: 5:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LRMR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
